Data / Drug companies / Oncora Pharma, LLC
Oncora Pharma, LLC: 49 products in the FDA NDC directory, labeler code 85477
Oncora Pharma, LLC (labeler code 85477) lists 49 products in the FDA National Drug Code Directory, covering 25 finished drugs by generic name. By type: 43 prescription drugs, 6 over the counter drugs. Its main marketing category is other unapproved drugs. The newest product started marketing on October 28, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 85477
- Products in commercial distribution
- 49
- Packages
- 49
- Finished drugs by generic name
- 25
- Prescription products
- 43
- Over the counter products
- 6
- Flagged as original packager
- 42 of 42 products that carry the flag
- Started marketing in the last 12 months
- 34
- Earliest marketing start
- July 12, 2023
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Other unapproved drugs | 41 | 83.7% |
| Over the counter monograph drugs | 6 | 12.2% |
| Generic drugs (ANDA) | 2 | 4.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 43 | 87.8% |
| Over the counter drugs | 6 | 12.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Folate, vitamin d3 | 2 | 2 |
| Methyl salicylate | 2 | 24 |
| Lidocaine hcl | 2 | 48 |
| Urea 41% | 2 | 1 |
| Lidexa | 1 | 1 |
| Urea 40.5 cream | 1 | 1 |
| Hydrocortisone 2% | 1 | 2 |
| Urea 41 | 1 | 1 |
| Tolnaftate | 1 | 99 |
| Urea | 1 | 17 |
| Ketoprofen | 1 | 5 |
| Topicaine ultra | 1 | 1 |
| Methenamine mandelate | 1 | 5 |
| Lidocaine 4% | 1 | 45 |
| Lidovara | 1 | 1 |
| Collavera | 1 | 1 |
| Hydravex | 1 | 1 |
| Lidocaine 2.8 | 1 | 1 |
| Hydralyn | 1 | 1 |
| Methocarbamol | 1 | 67 |
| Hydrocortisone | 1 | 171 |
| Numyra | 1 | 1 |
| Lidospra | 1 | 1 |
| Spravex | 1 | 1 |
| Lidomar | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 16 | 32.7% |
| Gel | 11 | 22.4% |
| Cream | 8 | 16.3% |
| Capsule | 6 | 12.2% |
| Spray | 2 | 4.1% |
| Liquid | 1 | 2% |
| Tablet, chewable | 1 | 2% |
| Solution | 1 | 2% |
| Patch | 1 | 2% |
| Tablet, coated | 1 | 2% |
| Lotion | 1 | 2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Dermoyrx | 85477-910 | Cream | Other unapproved drugs | October 28, 2026 |
| Mivara Mini | 85477-935 | Tablet | Other unapproved drugs | October 22, 2026 |
| Folivex | 85477-906 | Tablet | Other unapproved drugs | October 22, 2026 |
| Lidoryx 5% | 85477-731 | Gel | Other unapproved drugs | October 22, 2026 |
| Nuvexa | 85477-313 | Gel | Other unapproved drugs | October 22, 2026 |
| Spravex | 85477-327 | Spray | Other unapproved drugs | October 20, 2026 |
| Mirexa Mini | 85477-925 | Tablet | Other unapproved drugs | August 25, 2026 |
| Lidomar | 85477-326 | Lotion | Over the counter monograph drugs | August 25, 2026 |
| LidoSpra | 85477-325 | Spray | Other unapproved drugs | August 25, 2026 |
| Numyra | 85477-312 | Gel | Other unapproved drugs | August 23, 2026 |
| LidexaGel 5% | 85477-730 | Gel | Other unapproved drugs | July 1, 2026 |
| Minovia Mini | 85477-924 | Tablet | Other unapproved drugs | June 24, 2026 |
| Folvyris | 85477-823 | Tablet | Other unapproved drugs | May 1, 2026 |
| Tolfyra | 85477-331 | Liquid | Over the counter monograph drugs | May 1, 2026 |
| Evara | 85477-308 | Cream | Other unapproved drugs | April 29, 2026 |
| Methenamine Mandelate | 85477-115 | Solution | Other unapproved drugs | April 20, 2026 |
| Vitavera | 85477-513 | Tablet, chewable | Other unapproved drugs | April 7, 2026 |
| Urea 41 | 85477-306 | Cream | Other unapproved drugs | March 6, 2026 |
| Topicaine Ultra | 85477-307 | Gel | Over the counter monograph drugs | March 1, 2026 |
| Ketoprofen | 85477-111 | Capsule | Generic drugs (ANDA) | March 1, 2026 |
| Lidexa | 85477-330 | Cream | Other unapproved drugs | February 26, 2026 |
| Collavera | 85477-305 | Gel | Other unapproved drugs | February 26, 2026 |
| Lidovara | 85477-303 | Gel | Other unapproved drugs | February 26, 2026 |
| Probentra | 85477-712 | Capsule | Other unapproved drugs | February 23, 2026 |
| Microvara | 85477-711 | Capsule | Other unapproved drugs | February 23, 2026 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.